10 years of experience with thalidomide in multiple myeloma patients: Report of the Czech Myeloma Group
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216224%3A14110%2F13%3A00070584" target="_blank" >RIV/00216224:14110/13:00070584 - isvavai.cz</a>
Alternative codes found
RIV/65269705:_____/13:#0002107 RIV/00179906:_____/13:10140041 RIV/00064173:_____/13:#0000375 RIV/00098892:_____/13:#0000484 and 3 more
Result on the web
<a href="http://dx.doi.org/10.1016/j.leukres.2013.06.019" target="_blank" >http://dx.doi.org/10.1016/j.leukres.2013.06.019</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1016/j.leukres.2013.06.019" target="_blank" >10.1016/j.leukres.2013.06.019</a>
Alternative languages
Result language
angličtina
Original language name
10 years of experience with thalidomide in multiple myeloma patients: Report of the Czech Myeloma Group
Original language description
We analyzed 1156 multiple myeloma (MM) patients treated with thalidomide. The overall response rate was 63.6%, with complete remission in 13.4%. Combined regimens had better outcomes than thalidomide plus dexamethasone or single agent thalidomide. Thalidomide was not able to overcome adverse cytogenetics. Superior results were seen in patients undergoing subsequent autologous stem cell transplantation. The rate of adverse events was low. Thalidomide has a strong potential to improve response and survival measures in patients with standard risk MM. Combined regimens should be used, with lower doses of thalidomide. High risk myelomas should be treated individually.
Czech name
—
Czech description
—
Classification
Type
J<sub>x</sub> - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)
CEP classification
FD - Oncology and haematology
OECD FORD branch
—
Result continuities
Project
Result was created during the realization of more than one project. More information in the Projects tab.
Continuities
Z - Vyzkumny zamer (s odkazem do CEZ)
Others
Publication year
2013
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Leukemia Research
ISSN
0145-2126
e-ISSN
—
Volume of the periodical
37
Issue of the periodical within the volume
9
Country of publishing house
GB - UNITED KINGDOM
Number of pages
7
Pages from-to
1063-1069
UT code for WoS article
000324097600014
EID of the result in the Scopus database
—